National Blood Cancer Registry and Biobank

The NBCR and Biobank was established by the ALLG in 2012 to collect information on acute myeloid leukaemia (AML) clinical practice and as a pathway for registration to ALLG investigator-initiated clinical trials.

As at 1^st August 2020, over 2,000 patients participated in our National Blood Cancer Registry. Thanks to these patients who volunteer to be a part of the NBCR, we are able to continue to advance our clinical trials, research and understanding into these types of cancers.

This year we thank the NBCR sponsors for their support including AbbVie, Astellas, Pfizer and Amgen – for their commitment to the delivery of real-world clinical data.

For more information follow the link to view the Annual Review: https://www.allg.org.au/